Anti-Inflammatory Effects of Combined Budesonide/Formoterol in COPD Exacerbations

REFERENCES

• Niewoehner D E, Erbland M L, Deupree R H, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 1999; 340(25)1941–1947
   PubMed Web of Science ®Google Scholar
• Davies L, Angus R M, Calverley P M. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999; 354(9177)456–460
   PubMed Web of Science ®Google Scholar
• Maltais F, Ostinelli J, Bourbeau J, et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med 2002; 165(5)698–703
   PubMed Web of Science ®Google Scholar
• O'Byrne P M, Bisgaard H, Godard P P, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005; 171(2)129–136
   PubMed Web of Science ®Google Scholar
• Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21(1)74–81
   PubMed Web of Science ®Google Scholar
• Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361(9356)449–456
   PubMed Web of Science ®Google Scholar
• Barczyk A, Sozanska E, Trzaska M, et al. Decreased levels of myeloperoxidase in induced sputum of patients with COPD after treatment with oral glucocorticoids. Chest 2004; 126(2)389–393
   PubMed Web of Science ®Google Scholar
• Culpitt S V, Rogers D F, Shah P, et al. Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 167(1)24–31
   PubMed Web of Science ®Google Scholar
• Confalonieri M, Mainardi E, Della Porta R, et al. Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease. Thorax 1998; 53(7)583–585
   PubMed Web of Science ®Google Scholar
• Hattotuwa K L, Gizycki M J, Ansari T W, et al. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med 2002; 165(12)1592–1596
   PubMed Web of Science ®Google Scholar
• Balbi B, Majori M, Bertacco S, et al. Inhaled corticosteroids in stable COPD patients: do they have effects on cells and molecular mediators of airway inflammation?. Chest 2000; 117(6)1633–1637
   PubMed Web of Science ®Google Scholar
• Llewellyn-Jones C G, Harris T A, Stockley R A. Effect of fluticasone propionate on sputum of patients with chronic bronchitis and emphysema. Am J Respir Crit Care Med 1996; 153(2)616–621
   PubMed Web of Science ®Google Scholar
• Wilson S J, Wallin A, Della-Cioppa G, et al. Effects of budesonide and formoterol on NF-kappaB, adhesion molecules, and cytokines in asthma. Am J Respir Crit Care Med 2001; 164(6)1047–1052
   PubMed Web of Science ®Google Scholar
• Wallin A, Sandstrom T, Soderberg M, et al. The effects of regular inhaled formoterol, budesonide, and placebo on mucosal inflammation and clinical indices in mild asthma. Am J Respir Crit Care Med 1999; 159(1)79–86
   PubMed Web of Science ®Google Scholar
• Fujimoto K, Yasuo M, Urushibata K, et al. Airway inflammation during stable and acutely exacerbated chronic obstructive pulmonary disease. Eur Respir J 2005; 25(4)640–646
   PubMed Web of Science ®Google Scholar
• Mercer P F, Shute J K, Bhowmik A, et al. MMP-9, TIMP-1 and inflammatory cells in sputum from COPD patients during exacerbation. Respir Res 2005; 6: 151
   PubMed Web of Science ®Google Scholar
• Pizzichini E, Pizzichini M M, Gibson P, et al. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med 1998; 158: 1511–1517, (5 Pt 1)
   PubMed Web of Science ®Google Scholar
• Brightling C E, Monteiro W, Ward R, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2000; 356(9240)1480–1485
   PubMed Web of Science ®Google Scholar
• Brightling C E, McKenna S, Hargadon B, et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax 2005; 60(3)193–198
   PubMed Web of Science ®Google Scholar
• Bathoorn D, Liesker J JW, Postma D S, Bondesson E, Koëter G H, van Oosterhout A JM, Kerstjens H AM. Anti-inflammatory effect of combined budesonide/formoterol treatment in COPD exacerbations. Proceedings of the American Thoracic Society 2006; 3: A605
   Google Scholar
• Bathoorn D, Liesker J JW, Postma D S, Koëter G H, Kerstjens H AM. Change in inflammation during COPD exacerbations. Eur Respir J 2005; 26(Suppl. 49)15s
   PubMed Web of Science ®Google Scholar
• Quanjer P H, Tammeling G J, Cotes J E, et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993; 16: 5–40
   PubMedGoogle Scholar
• Davies L, Angus R M, Calverley P M. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999; 354(9177)456–460
   PubMed Web of Science ®Google Scholar
• Leidy N K, Schmier J K, Jones M K, et al. Evaluating symptoms in chronic obstructive pulmonary disease: validation of the Breathlessness, Cough and Sputum Scale. Respir Med 2003; 97(Suppl A:)59–S70
   PubMedGoogle Scholar
• van der Molen T, Willemse B W, Schokker S, et al. Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual Life Outcomes 2003; 1(1)13
   PubMedGoogle Scholar
• Rutgers S R, Timens W, Kaufmann H F, et al. Comparison of induced sputum with bronchial wash, bronchoalveolar lavage and bronchial biopsies in COPD. Eur Respir J 2000; 15(1)109–115
   PubMed Web of Science ®Google Scholar
• Pizzichini M M, Pizzichini E, Clelland L, et al. Sputum in severe exacerbations of asthma: kinetics of inflammatory indices after prednisone treatment. Am J Respir Crit Care Med 1997; 155(5)1501–1508
   PubMed Web of Science ®Google Scholar
• Kocks J W, Tuinenga M G, Uil S M, et al. Health status measurement in COPD: the minimal clinically important difference of the clinical COPD questionnaire. Respir Res 2006; 7: 62
   PubMed Web of Science ®Google Scholar
• Saetta M, Di Stefano A, Maestrelli P, et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 1994; 150: 1646–1652, (6 Pt 1)
   PubMed Web of Science ®Google Scholar
• Gan W Q, Man S F, Sin D D. Effects of inhaled corticosteroids on sputum cell counts in stable chronic obstructive pulmonary disease: a systematic review and a meta-analysis. BMC Pulm Med 2005; 5(1)3
   PubMedGoogle Scholar
• Barnes N C, Qiu Y S, Pavord I D, et al. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 2006; 173(7)736–743
   PubMed Web of Science ®Google Scholar
• Takatsu K. Interleukin 5 (IL-5) and its receptor. Microbiol Immunol 1991; 35(8)593–606
   PubMed Web of Science ®Google Scholar
• Emerman C L, Connors A F, Lukens T W, et al. A randomized controlled trial of methylprednisolone in the emergency treatment of acute exacerbations of COPD. Chest 1989; 95(3)563–567
   PubMed Web of Science ®Google Scholar
• Thompson W H, Nielson C P, Carvalho P, Charan N BJ CJ. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med 1996; 154: 407–412
   PubMed Web of Science ®Google Scholar
• Wood-Baker R R, Gibson P G, Hannay M, et al. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005, (1):CD001288
   Web of Science ®Google Scholar
• Morice A H, Morris D, Lawson-Matthew P. A comparison of nebulized budesonide with oral prednisolone in the treatment of exacerbations of obstructive pulmonary disease. Clin Pharmacol Ther 1996; 60(6)675–678
   PubMed Web of Science ®Google Scholar
• Fujimoto K, Kubo K, Yamamoto H, et al. Eosinophilic inflammation in the airway is related to glucocorticoid reversibility in patients with pulmonary emphysema. Chest 1999; 115(3)697–702
   PubMed Web of Science ®Google Scholar
• Rutgers S R, Timens W, Kaufmann H F, et al. Comparison of induced sputum with bronchial wash, bronchoalveolar lavage and bronchial biopsies in COPD. Eur Respir J 2000; 15(1)109–115
   PubMed Web of Science ®Google Scholar
• Meijer R J, Kerstjens H A, Arends L R, et al. Effects of inhaled fluticasone and oral prednisolone on clinical and inflammatory parameters in patients with asthma. Thorax 1999; 54(10)894–899
   PubMed Web of Science ®Google Scholar
• Bathoorn E, Liesker J, Postma D, Koeter G, van Oosterhout A J, Kerstjens H A. Safety of sputum induction during exacerbations of COPD. Chest 2007; 131(2)432–438
   PubMed Web of Science ®Google Scholar
• Borger P, Vellenga E, Gringhuis S I, et al. Prostaglandin E2 differentially modulates IL-5 gene expression in activated human T lymphocytes depending on the costimulatory signal. J Allergy Clin Immunol 1998; 101: 231–240, (2 Pt 1)
   PubMed Web of Science ®Google Scholar